Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Scanlon

Showing results (251-260 of 272) with videos related to

Pageof 28
Sort By:
Clinical Endocrinology|June 1, 1986
Growth hormone responses to GRF 1-29 in patients with primary hypothyroidism before and during replacement therapy with thyroxineR Valcavi, V Jordan, C Dieguez, et al.
British Journal of Clinical Pharmacology|January 1, 1977
Effects of nomifensine, an inhibitor of endogenous catecholamine re-uptake, in acromegaly, in hyperprolactinaemia, and against stimulated prolactin release in manM F Scanlon, A Gomez-Pan, B Mora, et al.
Cancer|March 1, 1979
Symptomatology as an indicator of recurrent or metastatic breast cancerD P Winchester, S F Sener, J D Khandekar, et al.
British Medical Journal (Clinical Research Ed.)|March 29, 1986
Trial of strategy for reducing the use of laboratory testsF G Fowkes, R Hall, J H Jones, et al.
Clinical Endocrinology|April 1, 1997
Treatment of macroprolactinoma with cabergoline: a study of 85 patientsC I Ferrari, R Abs, J S Bevan, et al.
The Journal of Clinical Endocrinology and Metabolism|September 11, 2001
The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancerJ C Smith, S Bennett, L M Evans, et al.
Journal of Surgical Oncology|August 1, 1984
Treatment of breast carcinoma recurrent after adjuvant chemoimmunotherapyS J Rabadi, M Haid, E F Scanlon, et al.
The Journal of Clinical Endocrinology and Metabolism|November 1, 1983
Exaggerated circadian variation in basal thyrotropin (TSH) and in the dopaminergic inhibition of TSH release in pathological hyperprolactinemia: evidence against a hypothalamic dopaminergic defectM D Rodriguez-Arnao, J R Peters, S M Foord, et al.
Breast Cancer Research and Treatment|October 1, 1987
A breast cancer Nutrition Adjuvant Study (NAS): protocol design and initial patient adherenceR T Chlebowski, D W Nixon, G L Blackburn, et al.
European Journal of Endocrinology|March 4, 2000
The effect of GH replacement therapy on endothelial function and oxidative stress in adult growth hormone deficiencyL M Evans, J S Davies, R A Anderson, et al.
Pageof 28

Showing results (251-260 of 272) with videos related to

Sort By:
Pageof 28
Clinical Endocrinology|June 1, 1986
Growth hormone responses to GRF 1-29 in patients with primary hypothyroidism before and during replacement therapy with thyroxineR Valcavi, V Jordan, C Dieguez, et al.
British Journal of Clinical Pharmacology|January 1, 1977
Effects of nomifensine, an inhibitor of endogenous catecholamine re-uptake, in acromegaly, in hyperprolactinaemia, and against stimulated prolactin release in manM F Scanlon, A Gomez-Pan, B Mora, et al.
Cancer|March 1, 1979
Symptomatology as an indicator of recurrent or metastatic breast cancerD P Winchester, S F Sener, J D Khandekar, et al.
British Medical Journal (Clinical Research Ed.)|March 29, 1986
Trial of strategy for reducing the use of laboratory testsF G Fowkes, R Hall, J H Jones, et al.
Clinical Endocrinology|April 1, 1997
Treatment of macroprolactinoma with cabergoline: a study of 85 patientsC I Ferrari, R Abs, J S Bevan, et al.
The Journal of Clinical Endocrinology and Metabolism|September 11, 2001
The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancerJ C Smith, S Bennett, L M Evans, et al.
Journal of Surgical Oncology|August 1, 1984
Treatment of breast carcinoma recurrent after adjuvant chemoimmunotherapyS J Rabadi, M Haid, E F Scanlon, et al.
The Journal of Clinical Endocrinology and Metabolism|November 1, 1983
Exaggerated circadian variation in basal thyrotropin (TSH) and in the dopaminergic inhibition of TSH release in pathological hyperprolactinemia: evidence against a hypothalamic dopaminergic defectM D Rodriguez-Arnao, J R Peters, S M Foord, et al.
Breast Cancer Research and Treatment|October 1, 1987
A breast cancer Nutrition Adjuvant Study (NAS): protocol design and initial patient adherenceR T Chlebowski, D W Nixon, G L Blackburn, et al.
European Journal of Endocrinology|March 4, 2000
The effect of GH replacement therapy on endothelial function and oxidative stress in adult growth hormone deficiencyL M Evans, J S Davies, R A Anderson, et al.
Pageof 28